Blood oxygenation systems are used for short term respiratory support, such as during coronary artery bypass graft surgeries or for acute respiratory distress syndrome patients. In current systems, blood is oxygenated by pumping oxygen through an inner, hollow fiber pumping blood though a larger, outer fiber that encapsulates the inner fiber. The walls of the inner fiber are permeable to oxygen and allow for the oxygenation of blood near the inner fiber. Current oxygenation systems maintain a laminar blood flow, only allowing the oxygenation of red blood cells within a close proximity of the permeable membrane.
According to one aspect of the disclosure, a microfluidic oxygenation device includes a first polymer layer defining a first oxygen flow channel. The device also includes a second polymer layer defining a first blood flow channel. The first blood flow channel overlaps the first oxygen flow channel, and the two channels are separated by a permeable membrane that allows communication between the channels at overlapping portions. Additionally, first blood flow channel further includes at least one passive mixing element along at least one wall. The passive mixing element is configured to redistribute a fluid flowing through the first blood flow channel within the channel.
In some implementations, the passive mixing element is one of a straight ridge, an angled ridge, a chevron canal, a dome, a cone, a pit or a post. In some implementations, a first fluid, such as oxygen, flows through the first oxygen flow channel and a second fluid, such as blood, flows through the first blood flow channel.
In some implementations, the height or depth of the passive mixing element is less than about 30% of the height of the first blood flow channel, and the passive mixing elements are incorporated into the floor of the first blood flow channel. In other implementations, the height of the first blood flow channel is between about 10 and 100 microns and the membrane thickness is between about 10 and about 50 microns. In yet other implementations, the length of the first oxygen flow channel and the first blood flow channel is between about 1 mm and 50 mm and the width is between about 100 microns and 200 microns.
In other implementations, the membrane is permeable to oxygen and carbon dioxide. In yet other implementations, the walls of the first blood flow channel are coated with an anticoagulant. In yet other implementations, the device includes a second blood flow channel separated from the first oxygen flow channel by a second permeable membrane.
According to another aspect of the disclosure, a method for oxygenating deoxygenate blood includes providing a microfluidic device comprising a first polymer layer defining a first oxygen flow channel and a second polymer layer defining a first blood flow channel. The first blood flow channel also includes at least one passive mixing element. A membrane separates the first oxygen flow channel and the first blood flow channel and allows communication between the first oxygen flow channel and the first blood flow channel. The method also includes introducing partially deoxygenated blood into a proximal end of the microfluidic device, and flowing the partially deoxygenated blood through the device. Additionally, the method includes flowing oxygen through the first oxygen flow channel. Finally, oxygenated blood is received at a distal end of the microfluidic device.
In some implementations, the method also includes collecting partially deoxygenated blood from a patient, flowing the partially deoxygenated blood through the first blood flow channel to reoxygenate the blood, and returning the reoxygenated blood to the patient. In other implementations, the method further includes removing carbon dioxide from the partially deoxygenated blood as the partially deoxygenated blood flows through the first blood flow channel.
In yet other implementations, the method also includes flowing oxygen through the first oxygen flow channel from a first direction, and flowing blood through the first blood flow channel in a second direction opposite to the first direction. In some implementations, the blood is flowed through the first blood flow channel at 4-5 L/min and oxygen is transferred to the blood at a rate of about 150-200 mL/min.
The skilled artisan will understand that the figures, described herein, are for illustration purposes only. It is to be understood that in some instances various aspects of the described implementations may be shown exaggerated or enlarged to facilitate an understanding of the described implementations. In the drawings, like reference characters generally refer to like features, functionally similar and/or structurally similar elements throughout the various drawings. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of the teachings. The drawings are not intended to limit the scope of the present teachings in any way. The system and method may be better understood from the following illustrative description with reference to the following drawings in which:
The various concepts introduced above and discussed in greater detail below may be implemented in any of numerous ways, as the described concepts are not limited to any particular manner of implementation. Examples of specific implementations and applications are provided primarily for illustrative purposes.
The present system described herein generally relates to a system and method for oxygenating blood. Accordingly, in various implementations, the disclosure relates to oxygenating blood by passively mixing the blood as it flows through the blood oxygenation device. In certain implementations, the device includes a plurality of passive elements on one wall of the device to mix the flowing blood.
As illustrated in
In some implementations, the device 100 and the passive mixing elements 106 are fabricated in the substrate 104 using, for example, photolithographic techniques, injection molding, direct micromachining, deep RIE etching, hot embossing, or any combinations thereof.
The first flow channel 101 communicates with the second flow channel 102 via the membrane 103. In some implementations, the membrane 103 is permeable or semi-permeable to ions, molecules, cells or any combination thereof. For example, the membrane 103 may allow for oxygen to pass from the first flow channel 101 to the second flow channel 102 and carbon dioxide to pass from the second flow channel 102 to the first flow channel 101. However, in some implementations, the membrane 103 is not permeable to red blood cells. In some implementations, the membrane 103 is fabricated from a semi-porous or porous material, such as polyethersulfone or PDMS. In other implementations, the membrane 103 is created by electrospinning a polymer to create a flexible, porous polymer mesh.
The first flow channel 101 and the second flow channel 102 of device 100 run substantially parallel to one another, and, as described above, are separated by the membrane 103 at overlapping portions. In some implementations, the first flow channel 101 includes three smooth walls, with the fourth wall being the membrane 103. In other implementations, the device 100 includes additional flow channels to the left, right, and/or above the first flow channel 101. In some of these implementations the first flow channel 101 is also separated from these additional flow channels by a permeable membrane 103. In other implementations, the first flow channel is configured for the flow of a gas. For example, oxygen may be flowed through the first flow channel 101. In other implementations, the first flow channel 101 is configured to flow a liquid. For example, the flow first flow channel may be configured to flow blood.
The second flow channel 102 includes at least one passive mixing element 106 along at least one wall of the channel. In the implementation of device 100, the floor 105 includes passive mixing elements 106(1)-106(n). In other implementations, any wall of the first or second flow channel can include a passive mixing element 106. In some implementations, the floor, or other wall(s) that include a passive mixing element 106, is replaceable, such that different configurations of passive mixing elements can be used for different fluids. In yet other implementations the device 100, or components thereof, is disposable.
As described below, in some implementations, the passive mixing elements include a plurality of ridges, channels, protrusions, or any combination thereof. In some implementations the passive mixing elements 106(1)-106(n) span the entire length of a flow channel. In other implementations, the mixing elements 106 cover only a sub-portion of the total length of a flow channel 102. In yet other implementations, the passive mixing elements 106(1)-106(n) are grouped together. For example, the fluid flow channel 102 may contain a first type of passive mixing element 106 along a first portion of the flow channel 102 and then a second type of passive mixing element 106 along a second portion of the flow channel 102.
In some implementations the height or depth of a passive mixing element 106 is between about 5% and about 10%, between about 10% and about 20%, or between about 20% and 30% of the total height of the flow channel 102. In some implementations, each passive mixing element in a channel is the same height or depth. While in other implementations, the height or depth of the passive mixing elements changes along the length of the flow channel 102.
In some implementations, the width, height, and length of the first flow channel 101 and second flow channel 102 are the same. In other implementations, one or all of the dimensions between different flow channels is different. In some implementations, the height of the flow channels is between about 10 microns and 25 microns, between about 25 microns and 50 microns, or between about 50 microns and 100 microns. In some implementations the thickness of the membrane 103 is between about 10 microns and 25 microns, between about 25 microns and 50 microns, or between about 50 microns and 100 microns. In some implementations, the length of the flow channels is between about 1 mm and 10 mm, between about 10 mm and 50 mm, or between about 50 mm and 100 mm and the width is between about 100 microns and 200 microns, between 200 microns and 500 microns, or between about 500 microns and 1 cm.
In contrast,
As illustrated in
As illustrated in
In yet other implementations, the passive mixing elements 106 are designed to create vortices and other high and low pressure areas which drive the fluid towards the membrane 103. For example,
In some implementations, the passive mixing elements can be, but are not limited to, posts, mounds, ramps, pits, cones or any combination thereof.
As set forth above, and referring to
Next, the method 500 of oxygenating blood continues with the introduction of partially deoxygenated blood into a proximal end of the microfluidic device (step 502). In some implementations, the blood is directly collected form a patient and introduced into the device. For example, the device may be part of a heart-lung bypass system that oxygenates blood during surgery. In other implementations, the blood is collected, stored, and then oxygenated at a later time. For example, the blood may be collected during a blood drive and then oxygenated prior to being transfused into a patient. In some implementation, the blood is actively pumped through the device by an external pump, and in other implementations the blood is pumped through the device by the patient's heart.
The method 500 continues by flowing the partially deoxygenated blood through a first blood flow channel (step 503). As described above, the device includes at least one passive mixing element that inducing mixing within the channel as the blood travels the length of the device. In some implementations, the blood is thinned with a blood thinning agent such as the drug Coumadin or Heparin. In some implementations, the walls of the blood flow channels are coated with an anticoagulant.
Responsive to flowing blood through the first blood flow channel, the method 500 continues by flowing oxygen through a first oxygen flow channel (step 504). Referring to
The method 500 continues, with the collection of the oxygenated blood at a distal end of the microfluidic channel. In some implementations, the oxygenated blood is transfused directly back into the patient from which it was collected. In other implementations, the blood is collected and stored for later transfusion or experimentation.
This application claims priority from Provisional U.S. Patent Application 61/567,104, filed Dec. 5, 2011, incorporated herein by reference in its entirety.
This invention was made with government support under Grant No. R21HL106585 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2876769 | Cordova | Mar 1959 | A |
| 3489647 | Kolobow | Jan 1970 | A |
| 3738813 | Esmond | Jun 1973 | A |
| 3847211 | Fischel et al. | Nov 1974 | A |
| 4620965 | Fukusawa et al. | Nov 1986 | A |
| 4756835 | Wilson | Jul 1988 | A |
| 4997565 | Niesen | Mar 1991 | A |
| 5120445 | Colman | Jun 1992 | A |
| 5207639 | Cooper | May 1993 | A |
| 5254259 | Bellhouse et al. | Oct 1993 | A |
| 6241945 | Owen | Jun 2001 | B1 |
| 6514412 | Insley et al. | Feb 2003 | B1 |
| 6602468 | Patterson et al. | Aug 2003 | B2 |
| 7713544 | Chaikof et al. | May 2010 | B2 |
| 7759113 | Vacanti et al. | Jul 2010 | B2 |
| 7955504 | Jovanovic et al. | Jun 2011 | B1 |
| 8128822 | Browning et al. | Mar 2012 | B2 |
| 8137554 | Jovanovic et al. | Mar 2012 | B2 |
| 8266791 | Borenstein et al. | Sep 2012 | B2 |
| 20020182241 | Borenstein et al. | Dec 2002 | A1 |
| 20030121841 | Harttig et al. | Jul 2003 | A1 |
| 20030175149 | Searles et al. | Sep 2003 | A1 |
| 20050202557 | Borenstein et al. | Sep 2005 | A1 |
| 20060136182 | Vacanti et al. | Jun 2006 | A1 |
| 20060173394 | Stroock et al. | Aug 2006 | A1 |
| 20070119771 | Schukar et al. | May 2007 | A1 |
| 20080093298 | Browning et al. | Apr 2008 | A1 |
| 20090081079 | Johns | Mar 2009 | A1 |
| 20090234332 | Borenstein et al. | Sep 2009 | A1 |
| 20100098742 | Vacanti et al. | Apr 2010 | A1 |
| 20100118642 | Ho et al. | May 2010 | A1 |
| 20100267136 | Vacanti et al. | Oct 2010 | A1 |
| 20110158847 | Charest et al. | Jun 2011 | A1 |
| 20110186165 | Borenstein et al. | Aug 2011 | A1 |
| 20110226686 | Maurer | Sep 2011 | A1 |
| 20120182609 | Borenstein et al. | Jul 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 1020080 45 621 | Mar 2010 | DE |
| 0 416 92 | Dec 1981 | EP |
| 1 408 562 | Oct 1975 | GB |
| 62-064372 | Mar 1987 | JP |
| 2003-093853 | Apr 2003 | JP |
| WO-02076529 | Oct 2002 | WO |
| WO-2006042079 | Apr 2006 | WO |
| WO-2010025926 | Mar 2010 | WO |
| WO-2011150216 | Dec 2011 | WO |
| WO-2011150216 | Dec 2011 | WO |
| Entry |
|---|
| Alex C. M. Kuo, Poly(dimethylsiloxane), Polymer data handbook, 1999 Oxford University Press, Inc. |
| Burgess, K. et al., “Towards microfabricated biohybrid artificial lung modules for chronic respiratory support,” Biomedical Microdevices, vol. 11, No. 12 Aug. 2008, pp. 117-127. |
| International Preliminary Report on Patentability dated Dec. 6, 2012, International application No. PCT/US2011/038148, International filing date May 26, 2011. |
| International Search Report and Written Opinion, International application No. PCT/US2012/067971, International filing date Dec. 5, 2012. |
| International Search Report, International Application No. PCT/US2010/062537, International Filing Date Dec. 30, 2010. |
| International Preliminary Report on Patentability mailed Jul. 12, 2012, International application No. PCT/US2010/062537, International filing date Dec. 30, 2010. |
| US Notice of Allowance in U.S. Appl. No. 13/116,219 DTD Jun. 14, 2013. |
| US Office Action in U.S. Appl. No. 12/981,903 DTD Feb. 22, 2013. |
| US Office Action in U.S. Appl. No. 12/981,903 DTD Aug. 30, 2012. |
| International Preliminary Report on Patentability mailed on Jun. 19, 2014 in PCT Application No. PCT/US2012/067971. |
| Stroock, et al., “Chaotic Mixer for Microchannels”, Science, vol. 295, pp. 647-651, Jan. 25, 2002. |
| US Office Action in U.S. Appl. No. 12/981,903 dated Jul. 30, 2014. |
| Wu et al., “Construction of Microfluidic Chips Using Polydimethylsiloxane for Adhesive Bonding,” Lab on a Chip, 5:1393-1398 (2005). |
| First Office Action issued in Australian Patent Application No. 2010339409 dated Sep. 29, 2014. |
| First Office Action issued on Jul. 17, 2014 in Chinese Patent Application No. 2011800367123. |
| Office Action issued Dec. 4, 2014 in Japanese Patent Application No. 2012-547304. |
| Patent Examination Report No. 1 in Australian Patent Application No. 2011258203, dated Nov. 4, 2014. |
| US Notice of Allowance in U.S. Appl. No. 12/981,903 DTD Feb. 2, 2015. |
| Borenstein et al., “Microfabrication Technology for Vascularized Tissue Engineering,” Biomedical Microdevices, 4(3):167-175 (2002). |
| Hongkai et al., “Construction of Microfluidic Chips Using Polydimethylsiloxane for Adhesive Bonding,” Lab on a Chip, 5:1393-1398 (2005). |
| International Search Report in PCT/US2011/038148, dated Aug. 26, 2011. |
| Leclerc et al., “Cell Culture in 3-Dimensional Microfluidic Structure of PDMS (polydimethylsiloxane),” Biomedical Microdevices, 5(2):109-114 (2003). |
| Office Action in U.S. Appl. No. 12/981,903 dated Sep. 11, 2013. |
| Yasuda, H. “Units of Gas Permeability Constants”, Journal of Applied Polymer Science, 1975, vol. 19, pp. 2529-2536. |
| Notice of Allowance in U.S. Appl. No. 13/116,219 dated Oct. 4, 2013. |
| Office Action issued Mar. 26, 2015 in Japanese Patent Application No. 2013-512244. |
| International Search Report and Written Opinion mailed Jul. 17, 2015 in PCT Application No. PCT/US2015/027321. |
| Number | Date | Country | |
|---|---|---|---|
| 20130144266 A1 | Jun 2013 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61567104 | Dec 2011 | US |